617
Participants
Start Date
August 31, 2006
Primary Completion Date
November 30, 2006
Study Completion Date
April 30, 2008
azelastine hydrochloride 0.15% Nasal Spray
1644 mcg, 2 sprays per nostril twice daily AM \& PM)
azelastine hydrochloride 0.15% and Placebo
822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
Azelastine 0.1%, Nasal Spray
1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
Allergy and Asthma Institue of Rochester, Rochester
Allergy and Clinical Immunology Associates, Pittsburgh
Valley Clinical Research Center, Easton
Allergy and Asthma Consultants of NJ-PA, P.C, Collegeville
Institute for Asthma and Allergy, P.C., Wheaton
North Carolina Clinical Research, Raleigh
Coastal Allergy and Asthma P.C., Savannah
Clinical Research Center, Cincinnati
Clinical Research Institute, Minneapolis
Kansas City Allergy and Asthma, Overland Park
The Asthma and Allergy Center, PC, Papillion
Oklahoma Institute of Allergy and Asthma, Edmond
AARA Research Center, Dallas
Research Across America, Dallas
Allergy and Asthma Center, Waco
Central Texas Health Research, New Braunfels
Sylvana Research Associates, San Antonio
Allergy Asthma Associates Research Dept., Austin
Colorado Allergy and Asthma Centers, PC, Denver
The William Storms Allergy Clinic, Colorado Springs
Allergy Research Foundation, Los Angeles
West Coast Clinical Trials, Long Beach
Allergy Associates Medical Group, San Diego
Southern California Research, Mission Viejo
AABI Associates Medical Group, Fountain Valley
Allergy and Asthma Associates of CA, San Jose
Allergy Medical Group, Roseville
Northeast Medical Research Associates, Inc., North Dartmouth
Atlantic Allergy, Asthma & Immunology, Ocean City
Princeton Center for Clinical Research, Skillman
Lead Sponsor
Meda Pharmaceuticals
INDUSTRY